caa a22 4500 463200640 CHVBK 20180405153111.0 cr unu---uuuuu 170326e20071101xx s 000 0 eng 10.1007/s10014-007-0222-4 doi (NATIONALLICENCE)springer-10.1007/s10014-007-0222-4 Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis [Elektronische Daten] [Keiichi Sakai, Kazuhiro Hongo, Yuichiro Tanaka, Jun Nakayama] The prognosis of chordomas is difficult to predict based solely on histological findings. The purpose of this study was to assess the immunohistochemical expression of the proliferation marker Ki-67 antigen and the expression of p53 in skull base chordomas and to relate their expressions to the outcome. We examined the expression of p53 and the MIB-1 labeling index (LI), assessed by Ki-67 expression, in 19 tumors (initial, n = 11; recurrent, n = 8) from 11 patients. The correlation among the MIB-1 LI, p53 expression, and the clinical outcome was analyzed. The mean MIB-1 LI and p53 expression at the initial surgery were 5.6 ± 4.6% and 9.0 ± 9.4%, respectively. At the time of recurrence, the mean MIB-1 LI and p53 expression were 10.2 ± 7.4% and 16.5 ± 12.0%. The correlation between the MIB-1 LI and p53 expression at the initial and recurrent surgeries was highly significant (r = 0.948; P < 0.0001). The change in p53 expression from the initial to the recurrent chordomas was significantly greater in patients who died of tumor-related causes than in the surviving patients. In the surviving patients, the values for MIB-1 LI and p53 expression in the recurrent tumors were significantly higher in the disease-ongoing group than in the disease-free group. Our results suggest that determination of the immunohistochemical expression of p53 and Ki-67 antigen is helpful to predict tumor recurrence and prognosis in skull base chordomas. The Japan Society of Brain Tumor Pathology, 2007 Skull base chordoma nationallicence MIB-1 nationallicence p53 nationallicence Recurrence nationallicence Prognosis nationallicence Sakai Keiichi Department of Neurosurgery, Shinshu University School of Medicine, Asahi 3-1-1, 390-8621, Matsumoto, Japan aut Hongo Kazuhiro Department of Neurosurgery, Shinshu University School of Medicine, Asahi 3-1-1, 390-8621, Matsumoto, Japan aut Tanaka Yuichiro Department of Neurosurgery, Shinshu University School of Medicine, Asahi 3-1-1, 390-8621, Matsumoto, Japan aut Nakayama Jun Department of Pathology, Shinshu University School of Medicine, Matsumoto, Japan aut Brain Tumor Pathology Springer-Verlag 24/2(2007-11-01), 57-62 1433-7398 24:2<57 2007 24 10014 https://doi.org/10.1007/s10014-007-0222-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10014-007-0222-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sakai Keiichi Department of Neurosurgery, Shinshu University School of Medicine, Asahi 3-1-1, 390-8621, Matsumoto, Japan aut NATIONALLICENCE 700 1- Hongo Kazuhiro Department of Neurosurgery, Shinshu University School of Medicine, Asahi 3-1-1, 390-8621, Matsumoto, Japan aut NATIONALLICENCE 700 1- Tanaka Yuichiro Department of Neurosurgery, Shinshu University School of Medicine, Asahi 3-1-1, 390-8621, Matsumoto, Japan aut NATIONALLICENCE 700 1- Nakayama Jun Department of Pathology, Shinshu University School of Medicine, Matsumoto, Japan aut NATIONALLICENCE 773 0- Brain Tumor Pathology Springer-Verlag 24/2(2007-11-01), 57-62 1433-7398 24:2<57 2007 24 10014 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer